Galapagos Boasts ''Best-In-Class'' With Its RA JAK Inhibitor
This article was originally published in Scrip
Executive Summary
Galapagos NV has thrown down the gauntlet to its rivals in the JAK inhibitor space, saying new Phase II data support a potential "best-in-class" title for its drug candidate filgotinib in rheumatoid arthritis. AbbVie Inc. now has 60 days to decide whether it wants to take up its option to license the product, something which analysts say these data make almost inevitable.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.